Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Zogenix
>
PREDICTIONS
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="Anonymous, post: 5007207"]ZohydroTM ER (hydrocodone bitartrate extendedrelease)</p><p>Pharmacy Coverage Policy</p><p>Effective Date: February 20, 2014</p><p>Revision Date: N/A</p><p>Review Date: February 20, 2014</p><p>Line of Business: Commercial, Medicare</p><p>Policy Type: Prior Authorization</p><p>Page: 1 of 7</p><p><br /></p><p>Humana's documents are updated regularly online. When printed, the version of this document becomes uncontrolled. Do</p><p>not rely on printed copies for the most up‐to‐date version. Refer to <a href="http://apps.humana.com/tad/tad_new/home.aspx" target="_blank" class="externalLink ProxyLink" data-proxy-href="http://apps.humana.com/tad/tad_new/home.aspx" rel="nofollow">http://apps.humana.com/tad/tad_new/home.aspx</a> to</p><p>verify that this is the current version before utilizing.</p><p>Disclaimer</p><p>Description</p><p>Coverage Determination</p><p>Background</p><p>Medical Terms</p><p>References</p><p>Disclaimer</p><p>State and federal law, as well as contract language, including definitions and specific inclusions/</p><p>exclusions, take precedence over clinical policy and must be considered first in determining eligibility for coverage.</p><p>Coverage may also differ for our Medicare and/or Medicaid members based on any applicable Centers for</p><p>Medicare & Medicaid Services (CMS) coverage statements including National Coverage Determinations (NCD),</p><p>Local Medical Review Policies (LMRP) and/or Local Coverage Determinations. See the CMS website at</p><p><a href="http://www.cms.hhs.gov/" target="_blank" class="externalLink ProxyLink" data-proxy-href="http://www.cms.hhs.gov/" rel="nofollow">http://www.cms.hhs.gov/</a>. The member's health plan benefits in effect on the date services are rendered must be</p><p>used. Clinical policy is not intended to pre‐empt the judgment of the reviewing medical director or dictate to health</p><p>care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in</p><p>rendering appropriate care. Clinical technology is constantly evolving, and we reserve the right to review and</p><p>update this policy periodically. No part of this publication may be reproduced, stored in a retrieval system or</p><p>transmitted, in any shape or form or by any means, electronic, mechanical, photocopying or otherwise without</p><p>permission from Humana.</p><p>Description Zohydro ER (hydrocodone bitartrate extended‐release) is a potent synthetic opioid</p><p>pain reliever.</p><p>This agent is a pure mu‐agonist opioid whose principal therapeutic action is analgesia.</p><p>Zohydro ER (hydrocodone bitartrate extended‐release) is indicated for the</p><p>management of pain severe enough to require daily, around‐the‐clock, long‐term</p><p>opioid treatment and for which alternative treatment options are inadequate. This</p><p>agent is not intended for use as a prn analgesic. It is formulated to deliver the opioid</p><p>analgesic hydrocodone over twelve hours.</p><p>Hydrocodone bitartrate extended‐release is available as Zohydro ER: 10 mg, 15 mg,</p><p>20 mg, 30 mg, 40 mg, and 50 mg capsules.</p><p>ZohydroTM ER (hydrocodone bitartrate extended‐release)</p><p>Effective Date: 2/20/2014</p><p>Revision Date: N/A</p><p>Review Date: 2/20/2014</p><p>Line of Business: Commercial, Medicare</p><p>Policy Type: Prior Authorization</p><p>Page: 2 of 7[/QUOTE]</p><p><br /></p>
[QUOTE="Anonymous, post: 5007207"]ZohydroTM ER (hydrocodone bitartrate extendedrelease) Pharmacy Coverage Policy Effective Date: February 20, 2014 Revision Date: N/A Review Date: February 20, 2014 Line of Business: Commercial, Medicare Policy Type: Prior Authorization Page: 1 of 7 Humana's documents are updated regularly online. When printed, the version of this document becomes uncontrolled. Do not rely on printed copies for the most up‐to‐date version. Refer to [url]http://apps.humana.com/tad/tad_new/home.aspx[/url] to verify that this is the current version before utilizing. Disclaimer Description Coverage Determination Background Medical Terms References Disclaimer State and federal law, as well as contract language, including definitions and specific inclusions/ exclusions, take precedence over clinical policy and must be considered first in determining eligibility for coverage. Coverage may also differ for our Medicare and/or Medicaid members based on any applicable Centers for Medicare & Medicaid Services (CMS) coverage statements including National Coverage Determinations (NCD), Local Medical Review Policies (LMRP) and/or Local Coverage Determinations. See the CMS website at [url]http://www.cms.hhs.gov/[/url]. The member's health plan benefits in effect on the date services are rendered must be used. Clinical policy is not intended to pre‐empt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Clinical technology is constantly evolving, and we reserve the right to review and update this policy periodically. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any shape or form or by any means, electronic, mechanical, photocopying or otherwise without permission from Humana. Description Zohydro ER (hydrocodone bitartrate extended‐release) is a potent synthetic opioid pain reliever. This agent is a pure mu‐agonist opioid whose principal therapeutic action is analgesia. Zohydro ER (hydrocodone bitartrate extended‐release) is indicated for the management of pain severe enough to require daily, around‐the‐clock, long‐term opioid treatment and for which alternative treatment options are inadequate. This agent is not intended for use as a prn analgesic. It is formulated to deliver the opioid analgesic hydrocodone over twelve hours. Hydrocodone bitartrate extended‐release is available as Zohydro ER: 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, and 50 mg capsules. ZohydroTM ER (hydrocodone bitartrate extended‐release) Effective Date: 2/20/2014 Revision Date: N/A Review Date: 2/20/2014 Line of Business: Commercial, Medicare Policy Type: Prior Authorization Page: 2 of 7[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Zogenix
>
PREDICTIONS
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Zogenix
>
PREDICTIONS
>